Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Poster Session Abstracts

Abstract P6-03-05: Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient

Francois-Clement Bidard, Ck Ng, Ezgi Tulukcuoglu, S Piscuoglio, Stephanie Descroix, Laurent Mignot, Jean-Louis Viovy, Paul Cottu, Brigitte Sigal, Anne Vincent-Salomon, Britta Weigelt, Jean-Yves Pierga and Jorge Reis-Filho
Francois-Clement Bidard
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ck Ng
Memorial Sloan Kettering Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ezgi Tulukcuoglu
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S Piscuoglio
Memorial Sloan Kettering Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Descroix
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurent Mignot
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Louis Viovy
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Cottu
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brigitte Sigal
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne Vincent-Salomon
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Britta Weigelt
Memorial Sloan Kettering Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Yves Pierga
Institut Curie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Reis-Filho
Memorial Sloan Kettering Cancer Center
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.SABCS14-P6-03-05 Published May 2015
  • Article
  • Info & Metrics
Loading
Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX

Abstract

Background: HER3 is the only member of the EGFR family with an impaired kinase domain. Pre-clinical work has suggested that activating hotspot point mutations in HER3/ERBB3 may constitute drivers of tumor progression. Mutant HER3 oncogenic activity was shown to be dependent on HER2 signaling. In vitro and in vivo experiments have suggested that HER2-targeting therapies could be effective to block mutant HER3 oncogenic signaling. Through high-depth whole exome sequencing analysis of the primary breast cancer and liver metastasis of a patient with stage IV disease, we identified a clonal, activating HER3 mutation in both the primary tumor and metastasis, and sought to define whether this mutation would constitute a driver of the disease and be a therapeutic target.

Patient and method: A 46 yo women was diagnosed in 2012 with de novo synchronous metastatic breast cancer. Biopsies of the primary breast cancer and of the liver metastasis were performed before any treatment within the ESOPE prospective study (NCT01956552). Pathologic examination revealed a high-grade invasive ductal carcinoma with low expression of estrogen and progesterone receptors (both 20%) and intermediate HER2 (++) expression by immunohistochemical analysis without HER2 gene amplification by fluorescence in situ hybridization. While high-depth (250x) whole exome massively parallel sequencing (HiSeq) of the primary tumor and liver metastasis was ongoing, the patient received two lines of chemotherapy (anthracycline- and taxane-based). Data analysis revealed that both the primary tumor and the liver metastasis displayed a clonal G284R HER3 mutation at a high allelic frequency compatible with the distribution of a driver genetic alteration. Single nucleotide polymorphism (SNP6) arrays and sequencing confirmed the lack of HER2 gene amplification. At time of progression, after two lines of chemotherapy (05/2014), the patient had a baseline blood draw and PET-CT and was administered trastuzumab (6 mg/kg q3w) in combination with lapatinib (1250mg qd), with no chemotherapy.

Results: Treatment was well tolerated with no dose reduction. Protein-ligation assay (PLA) by rolling-circle amplification performed at baseline showed HER2-HER3 heterodimers in circulating tumor cells. After only 15 days of treatment, PET-CT displayed a complete metabolic response and a slight decrease of the diameter of liver metastasis (-20%). At day 21, no CTCs were detected in 7.5ml of peripheral blood and CA15.3 dropped from 45 (baseline) to 32 (upper limit = 30). ctDNA was also collected and is currently being analyzed. Dual blockade has been pursued; updated follow-up will be presented at the meeting.

Conclusion: HER3 mutations are particularly rare in breast cancer (<1% of breast cancers) and no trial is currently assessing the relevance of HER2-blockade in this subgroup. On the basis of an extreme response to dual HER2 blockade with no chemotherapy, we confirm the published preclinical data and suggest that these patients may benefit from anti-HER2 therapies. A prospective global registry for HER3 mutated breast cancers cases and their response to specific systemic therapies may facilitate the accrual of data to support the use of anti-HER2 agents in this patient population.

Citation Format: Francois-Clement Bidard, Ck Ng, Ezgi Tulukcuoglu, S Piscuoglio, Stephanie Descroix, Laurent Mignot, Jean-Louis Viovy, Paul Cottu, Brigitte Sigal, Anne Vincent-Salomon, Britta Weigelt, Jean-Yves Pierga, Jorge Reis-Filho. Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr P6-03-05.

Previous
Back to top
Cancer Research: 75 (9 Supplement)
May 2015
Volume 75, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract P6-03-05: Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract P6-03-05: Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient
Francois-Clement Bidard, Ck Ng, Ezgi Tulukcuoglu, S Piscuoglio, Stephanie Descroix, Laurent Mignot, Jean-Louis Viovy, Paul Cottu, Brigitte Sigal, Anne Vincent-Salomon, Britta Weigelt, Jean-Yves Pierga and Jorge Reis-Filho
Cancer Res May 1 2015 (75) (9 Supplement) P6-03-05; DOI: 10.1158/1538-7445.SABCS14-P6-03-05

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract P6-03-05: Dual HER2 blockade of an activating driver HER3 mutation: A proof of principle study in a metastatic breast cancer patient
Francois-Clement Bidard, Ck Ng, Ezgi Tulukcuoglu, S Piscuoglio, Stephanie Descroix, Laurent Mignot, Jean-Louis Viovy, Paul Cottu, Brigitte Sigal, Anne Vincent-Salomon, Britta Weigelt, Jean-Yves Pierga and Jorge Reis-Filho
Cancer Res May 1 2015 (75) (9 Supplement) P6-03-05; DOI: 10.1158/1538-7445.SABCS14-P6-03-05
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Poster Session Abstracts

  • Abstract P6-14-05: Phase 2 study evaluating the efficacy and safety of eribulin mesylate administered biweekly for patients with human epidermal growth factor receptor 2-negative metastatic breast cancer
  • Abstract P6-08-07: Decline in compliance to breast cancer screening in France: Results of the 5th EDIFICE survey
  • Abstract P6-08-04: National trends in mastectomy for operable breast cancers treated with neoadjuvant chemotherapy
Show more 3

Poster Session 6: Tumor Cell and Molecular Biology: Novel/Emerging Therapeutic Targets

  • Abstract P6-03-03: Enrichment of janus kinase-2 (JAK2)-amplified tumor cell populations in triple-negative breast cancers (TNBC) during chemotherapy treatment
  • Abstract P6-03-01: A phase Ib study of the CXCR1/2 inhibitor reparixin in combination with weekly paclitaxel in metastatic HER2 negative breast cancer – First analysis
  • Abstract P6-03-12: High MELK expression levels correlate with shorter overall survival in breast cancer
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement